期刊文献+

吉非替尼治疗老年晚期非小细胞肺癌55例

下载PDF
导出
摘要 老年局部晚期(IIb期)和转移性(Ⅳ期)非小细胞肺癌(NSCLC)患者在肺癌人数中约占70%左右,目前推荐的治疗标准是第3代化疗药物的单药治疗,部分体能评分较好的老年患者可接受标准的以铂类为基础的两药联合化疗。但是老年患者在一线化疗失败后大多不能耐受继续化疗,甚至很多患者因为体能评分差、化疗反应或不愿接受细胞毒药物治疗等而不能化疗。
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2009年第21期1225-1226,共2页 Chinese Journal of Clinical Oncology
  • 相关文献

参考文献10

  • 1姜宏宁,史崑,余敏.吉非替尼一线治疗老年非小细胞肺癌的临床观察[J].实用癌症杂志,2008,23(4):402-405. 被引量:8
  • 2Hanra EB. Treatment of advallced non-small-cell lung cancer:a review of current randomized clinical trials and an examination of emerging therapies. Cnacer Control, 2001, 8(15):326-336.
  • 3Lynch TJ. Bell DW. SordeUa R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer togeiftinib[J]. N EnglJ Med, 2004, 350(21): 2129.
  • 4孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
  • 5Massarelli E, Andre F, LiuDD, et al. A retrospective analysis of the outcome patients who have received two prio rchemotherapy regimens including platinum and doeetaxel for recurrent n non-sinai-cell lung cancer[J]. LungCancer, 2003, 39(1): 55.
  • 6Cappuzzo F, Hirseh F R, Rossi E, et al. Epidermal growth factor receptor gene and protein and getltirtib sensitivity in non-small-cell lung cancer[J].JNat Cnacer Inst, 2005, 97(9): 643.
  • 7Fukuoka M, Yano S, Giaccone G, et al. Mult-insfimtional ra- domized phase II trial of gefifinib for previously treated pafiens with advanced non-small-cell lung cancer. J Clin Oncol, 2003, (12) :2237-2246.
  • 8Stahel R, ROSSi A, Petruzelka L, et al. Lessons from the"Iressa"Expanded Access Programrne:gefitinib in special non-small-cell lung cancer patient populations. Br JCancer, 2003, 89 Suppl 2: S19- S23.
  • 9Argiris A, Mittal N. Gefitinib as first-line,compassionate use therapy in patients with .advanced non-small-cell lung cancer. Lung Cancer, 2004, 43 (3):317-322.
  • 10Shan NT, Kris MG, PaoW, et al. Practical management of patients with non-small-cell lung cancer treated with gefifinib[J]. J Clin Oncol, 2005.23(1): 165.

二级参考文献19

  • 1王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 2王岩,徐建明,宋三泰.表皮生长因子受体靶向药物作用机制与相关标志物的研究现状[J].中华肿瘤杂志,2005,27(9):573-576. 被引量:33
  • 3李宗泰.临床药理学[M].北京:人民卫生出版社,1998.82~83.
  • 4Egorin MJ. Cancer pharmareology in the older [J]. Sevnin Oncology, 1993,20( 1 ) :43.
  • 5Dy GK, AdjeiAA. Novel targets for lung cancer the rapy [M]. Part Ⅰ J Clin Oncol,2002,20:2881.
  • 6Baselga I, Rischin D, Ranson M,et al. Phase Ⅰ safety, pharmacokinetic,and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types [J]. Clin Oncol,2002,20(21 ) :4292.
  • 7Rossi A,Maione P, Del Gaizo F, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure two clinical cases[J]. Lung Cancer, 2005,47 ( 3 ) : 421.
  • 8Fubuoka M, Yano S, Graeeone G, et al. Multi-institutional random ized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer[J]. Clin Oncology,2003,21 (12) :2237.
  • 9LoRusso PM, Herbst RS, Rischln D, et al. Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J]. Clin Cancer Res ,2003,9 :2040.
  • 10Ranson M,Hammond LA,Ferry D,et al. ZD1839,a selective oral epidermal growth factor receptor-tyrosine Kinase inhibitor is well tolerated and active in patients with solid, malignant tumors:results of a phase Ⅰ trial[J]. Clin Oncol, 2002,20 : 2240.

共引文献309

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部